#United States #New York #Securities Fraud #Rosen Law Firm #INOVIO Pharmaceuticals

Investors of Inovio Pharmaceuticals Must Act

Investors who purchased securities from Inovio Pharmaceuticals, Inc. (NASDAQ: INO) during the class period, which runs from October 10, 2023, to December 26, 2025, are being alerted to an important upcoming deadline. The Rosen Law Firm, a well-known global advocate for investor rights, has announced that April 7, 2026, marks the deadline for potential lead plaintiffs to take action in the pending securities fraud litigation against Inovio.

This legal initiative is crucial for those who believe they have suffered from misleading information disseminated by Inovio throughout the aforementioned class period. If you have bought shares during this time, you might be eligible for financial compensation without incurring any upfront costs, as the Rosen Law Firm operates on a contingency fee basis.

How to Participate in the Case

If you wish to join the class action lawsuit, potential investors are advised to visit Rosen Law Firm's website or contact Phillip Kim, Esq., at 866-767-3653. You can also reach out via email at [email protected]. It’s essential to understand that filing as a lead plaintiff involves serving as a representative for other affected investors, guiding the litigation process.

Background on the Case

The lawsuit revolves around serious allegations that executives at Inovio Pharmaceuticals made false and misleading statements regarding their CELLECTRA device, a significant product for the company. Defendants allegedly understated manufacturing issues, affecting their ability to submit a critical Biologics License Application (BLA) for the INO-3107 product to the U.S. Food and Drug Administration (FDA) within the expected timeline. In essence, this misrepresentation inflated the perceived commercial potential of INO-3107, resulting in damages for investors once the truth emerged.

The Importance of Qualified Legal Representation

Choosing the right legal counsel is paramount. The Rosen Law Firm emphasizes its strong track record, having secured notable settlements in securities class actions, including one of the largest ever against a Chinese company. Their lead attorney, Laurence Rosen, has received recognition as a top plaintiffs' advocate, which underscores the firm's capabilities in navigating complex securities litigations. Investors are urged to opt for a law firm with proven experience rather than settling for middlemen that merely refer clients to other attorneys.

No Certification of Class Yet

It's important to note that, as of now, no class has been formally certified. Without this certification, investors may not be officially represented, unless they engage counsel independently. Moreover, participating as a lead plaintiff does not hinder your ability to benefit from any financial recovery. Members can also choose to remain absent from the lawsuit at this stage if they prefer.

Stay Updated

For ongoing updates about this case and other securities matters, interested parties can follow the Rosen Law Firm on platforms like LinkedIn, Twitter, and Facebook. By doing so, you’ll gain insights and important notifications concerning your rights as investors.

In summary, if you are among those who have invested in Inovio Pharmaceuticals during the class period, it is crucial to take immediate action before the April 7, 2026 deadline to safeguard your interests and potentially reclaim lost investments due to securities fraud.